KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for NovoCure (NVCR) over the last 12 years, with Q3 2025 value amounting to $5.7 million.

  • NovoCure's Capital Expenditures fell 4706.54% to $5.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.7 million, marking a year-over-year decrease of 2464.77%. This contributed to the annual value of $42.9 million for FY2024, which is 5817.74% up from last year.
  • According to the latest figures from Q3 2025, NovoCure's Capital Expenditures is $5.7 million, which was down 4706.54% from $5.5 million recorded in Q2 2025.
  • NovoCure's 5-year Capital Expenditures high stood at $14.3 million for Q4 2021, and its period low was $2.6 million during Q2 2021.
  • Over the past 5 years, NovoCure's median Capital Expenditures value was $6.4 million (recorded in 2022), while the average stood at $7.2 million.
  • As far as peak fluctuations go, NovoCure's Capital Expenditures soared by 14785.55% in 2021, and later crashed by 5494.61% in 2022.
  • NovoCure's Capital Expenditures (Quarter) stood at $14.3 million in 2021, then tumbled by 54.95% to $6.4 million in 2022, then grew by 6.06% to $6.8 million in 2023, then surged by 31.1% to $8.9 million in 2024, then tumbled by 36.76% to $5.7 million in 2025.
  • Its Capital Expenditures stands at $5.7 million for Q3 2025, versus $5.5 million for Q2 2025 and $10.6 million for Q1 2025.